ClinicalTrials.gg
CompletedNCT01840553Updated Mar 24, 2014

Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing

A Phase 3 interventional study of oral sodium phosphate tablets and polyethylene glycol in Colon Cleansing, sponsored by Laboratoires Mayoly Spindler. Completed at 19 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-24.

Sponsored by Laboratoires Mayoly Spindler · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
461
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of sodium phosphate tablets compared to split dose of 4 liters of PEG used in adults for bowel cleansing prior to colonoscopy.

02

Conditions studied

  • Colon Cleansing
03

In context

Lead sponsor

Laboratoires Mayoly Spindler is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged from 18 to 75 years (included).
  • Scheduled for a colonoscopy as an outpatient.
  • Normal renal function

Exclusion criteria

Exclusion Criteria:

  • Having a disease or condition as follows:

    • repeated episodes of nausea and vomiting
    • abdominal pain due to severe infection or requiring surgery
    • abnormal electrolytes values
    • congestive heart failure, unstable angina pectoris or recent myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass surgery within previous 3 months
    • known/suspected bowel obstruction, megacolon, ileus or intestinal perforation, or gastroparesis,
    • inflammatory bowel disease,
    • history of gastric stapling or bypass procedure or gastric retention
  • Sodium phosphate preparation taken within the past three weeks prior to colonoscopy.
  • Known allergy to any of the active ingredients or of the study drugs.
  • History of phenylketonuria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
461 participants (actual)

Study arms

  • Active comparator
    polyethylene glycol

    4 Liters of PEG administered split in 2 doses

    Drug: polyethylene glycol

  • Experimental
    oral sodium phosphate tablets

    oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid

    Drug: oral sodium phosphate tablets

06

What researchers measure

Primary outcomes

  1. overall quality of bowel cleansing

    Time frame: day 1

07

Study locations

19 sites
  • Hôpital Avicenne
    Bobigny, France
  • Polyclinique Bordeaux Nord Aquitaine
    Bordeaux, France
  • Hopital Edouard Herriot
    Lyon, France
  • Groupe Hospitalier Intercommunal Le Raincy-Montfermeil
    Montfermeil, France
  • CHU Hotel Dieu
    Nantes, France
  • Hopital l'Archet
    Nice, France
  • CHU Cochin
    Paris, France
  • Clinique Saint-Jean Languedoc
    Toulouse, France
  • Sana Klinikum Lichtenberg
    Berlin, Germany
  • Kreisklinik Biberach
    Biberach, Germany
  • Klinikum Heidenheim
    Heidenheim, Germany
  • Medizinische Klinik und Poliklinik II Munchen
    Munchen, Germany
  • Complejo Hospitalario de A Coruna
    A Coruna, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital de Fuenlabrada
    Fuenlabrada, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Hospital Clinico San Carlos
    Madrid, Spain
  • Hospital Universitarion Gregorio Maranon
    Madrid, Spain
  • Clinica Universidad de Navarra
    Pamplona, Spain
08

References and documents

Publications

  • Chaussade S, Schmocker C, Toulemonde P, Munoz-Navas M, O'Mahony V, Henri F. Phosphate tablets or polyethylene glycol for preparation to colonoscopy? A multicentre non-inferiority randomized controlled trial. Surg Endosc. 2017 May;31(5):2166-2173. doi: 10.1007/s00464-016-5214-1. Epub 2016 Nov 18. PubMed 27864718 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2013
First posted
Apr 25, 2013
Start
May 2013
Primary completionActual
Mar 2014
CompletionActual
Mar 2014
Last update
Mar 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01840553
Lead sponsor
Laboratoires Mayoly Spindler
Responsible party
Sponsor
First posted
Apr 25, 2013
Start date
May 2013
Primary completion
Mar 2014
Completion
Mar 2014
Last update
Mar 24, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium phosphate

Start the discussion